The New Medical Device Regulations of European Union replace the E.U's current Medical Device Directive (93/42/EEC) and the E.U's Directive on Active Implantable Medical Devices (90/385/EEC) According to the draft document, NB's would be placed under a strict regimen of super vision, although it remains unclear whether the intended sanctions could be implemented against the will of a Member State, should the need occur. The qualification requirements for auditing and reviewing NB staff are steeply increased. Greater emphasis will be placed on clinical data and the Clinical Evaluation. For implantable medical devices and Class III devices clinical investigations will be expected since equivalence will generally no longer be an acceptable approach, although some exceptions can be made. The proposed MDR attempts to make more transparent the periods for review by various parties for different activities. Implementation of Unique device identification helpful for the unambiguous identification of a specific device on the market.
INTRODUCTION
Ranging from simple sticking plasters and contact lenses to sophisticated pacemakers and hip replacements, cardiac stents medical devices and in vitro diagnostic medical devices are important to our health and quality of life. People rely on these devices every day and expect them to be safe and incorporate the latest progress in science and innovation. Medical devices within the EU are currently regulated by the following 3 directives [European Commission Regulations on medical and in-vitro diagnostic medical devices proposed by the Commission in 2012 will help to ensure that all medical devices from heart valves to sticking plasters to artificial hips are safe and perform well. To address this, the new rules will improve market surveillance and traceability as well as make sure that all medical devices are designed to reflect the latest scientific and technological state-of-the art. The rules will also provide more transparency and legal certainty for producers, manufacturers, importers, and help to strengthen international competitiveness and innovation in this strategic sector. The proposed MDR differs in several important ways from the EU's current directives for medical devices and active implantable medical devices. The most significant changes in the proposed regulation include:
PRODUCT SCOPE EXPANSION
The definition of medical devices and active implantable medical devices covered under the MDR will be significantly expanded to include devices that may not have a medical intended purpose, such as colored contact lenses and cosmetic implant devices and materials. Also expected to be included in the scope of the regulation are devices designed for the purpose of "prediction" of a disease or other health condition.
NEW DEFINITIONS -PLACING ON THE MARKET IS NOW EXPRESSLY COMMERCIAL
There are hosts of new definitions including of course for medical device, custom-made device and for making available on the market. Placing a device on the market is now defined to be something that takes place as part of a commercial activity (whether for charge or for free). It remains to be seen whether this will provide a loophole for organizations such as charities. The definition of serious adverse event is expanded to specifically include hospitalization, medical or surgical interventions to prevent life threatening injury or illness, chronic disease, foetal distress, foetal death or a congenital physical or mental impairment or birth defect, Nanomaterials are also explicitly defined in terms or particle sizes and proportions of agglomerates, as well as Fullerenes, graphene flakes and single-wall carbon nanotubes with one or more external dimensions below 1 nm deemed to be Nanomaterials. 
RECLASSIFICATION OF DEVICES ACCORDING TO RISK, CONTACT DURATION AND INVASIVENESS

IDENTIFICATION OF "QUALIFIED PERSON"
Device manufacturers will be required to identify at least one person within their organisation who is ultimately responsible for all aspects of compliance with the requirements of the new MDR. The organisation must document the specific qualifications of this individual relative to the required tasks.
STRONGER NOTIFIED BODY OVERSIGHT
One of the central pillars of the European reforms has been the strengthening of the oversight and capacity of Notified Bodies. The new regulations bring a much more rigorous designation process, with multiple parties involved in the designation process to ensure consistency and transparency. All Notified Bodies are required to re-apply for designation, with a lengthy review process likely to take at least 18 months.
RISK MANAGEMENT
Risk management concepts are embedded throughout the regulations. Students of the controversy over the Annexes to ISO 14971 will be relieved to learn that the essential requirements introduce a more pragmatic approach. The Annex I, Chapter I General Requirements deal at length with risk stating risks are required to be acceptable when weighed against the benefits to the patient" and going on to state that Manufacturers shall manage risks so that the residual risk associated with each hazard as well as the overall residual risk is judged acceptable. Along with the risk management, the new medical device regulations grant special power to notified bodies for increasing post market surveillance activities, it strengthen the European Union enforcement regime and help to reduce risk from unsafe devices. Sometimes in case of class III Devices annual safety report may require.
CLINICAL EVALUATION, POST MARKET FOLLOW UP AND IDENTIFICATION OF RESIDUAL RISK
The strengthening of clinical requirements has long been anticipated. The Final text retains the explicit requirements for clinical evaluation of all devices irrespective of class and is specific that clinical evaluation shall include consideration of all information sources including pre-clinical data, risk management, literature and direct clinical experience. Class III devices are required to have direct clinical trial data except in the specific circumstance of design iterations from a previous device where a justification can be provided based on review of testing or by comparison with another manufacturer's devices as a predicate but only if the other manufacturer will provide complete and perpetual access to the technical file information of the predicate. For preparing the clinical evaluation report well trained personals like biostatisticians, medical writers, product specialist and clinician who must sign off the report. Annual review of clinical evaluation must be takes place (especially for class III) and the reviews used to recalibrate risk management files. All class III devices, any device, which depends on predicate comparisons, must be subject to active post market clinical follow up, and again the information gained must feed into risk management review.
IMPLEMENTATION OF UNIQUE DEVICE IDENTIFICATION
The proposed MDR mandates the use of Unique Device Identification (UDI) mechanisms. The UDI is a series of numbers or alphabets followed by number characters that are created through a globally accepted device identification and coding standard. Easy traceability of device on the market. The UDI is comprised of the UDI-DI and the UDI-PI. This requirement is expected to increase the ability of manufacturers and Authorities to trace specific devices through the supply chain, and to facilitate the prompt and efficient recall of medical devices that have been found to present a safety risk with the help of Product & Device identifiers. In addition, the European Databank on Medical Devices (EUDAMED) is expected to be expanded to provide more efficient access to information on approved medical devices.
ECONOMIC OPERATORS -REGULATION FOR ALL:
The old MDD essentially provided requirements for manufacturers and their authorized representatives. The new Regulations introduce the concept of economic operator. That includes manufacturers, importers, distributors, market representatives, Notified Bodies, and the Regulations place specific requirements on each of these. Distributors and Importers are required to maintain detailed records Vol. 6, Issue 2 | magazine.pharmatutor.org
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and to actively participate in post market monitoring; European Representatives are to be held jointly and severally liable for safety of medical devices. Expect European commission representatives to insist on insurance cover and fees to be adjusted accordingly
REUSE OF SINGLE USE DEVICES AND IN-HOSPITAL MANUFACTURING
There has been considerable debate in the development of the regulations about reprocessing of single use devices, with some European countries strongly in favour of reprocessing and others less so. The Regulations actively contemplate reprocessing activities but make it clear that commercial reprocessors are to be considered manufacturers and subject to the full force of the regulations. However, there is a get-out clause for hospitals -where national authorities are empowered to allow reprocessing within hospitals to be conducted to a lower standard -providing the devices are not transferred outside to that facility. Hospitals also get a break on making their own devices. Hospitals and clinics are specifically exempted from the Regulations provided they don't supply anything they manufacturer outside of the hospital.
e-LABELING
There are a lot of implications for the information in labels and instruction for use within the regulations. Physical labeling continues to be mandated as in the medical devices directives, but now there is a requirement that for manufacturers who operate a website, labeling information must also be published there. e-labeling is allowed as a supplement but not instead of physical labeling. Instructions for Use (IFU) may be in electronic form but must conform to Regulation (EU) no 207/2012 on electronic instructions for use of medical devices. The European commission will be providing further guidance on the labelling requirements in relation to device containing hazardous substances.
MANY NEW REPORTS TO BE REVIEWED
Get used to some new acronyms. Manufacturers will need to prepare a Periodic Safety Update Report (PSUR), Post Market Clinical Follow Up (PMCF) reports and Summary of Safety and Clinical Performance. For higher risk devices these will need to be reviewed by the Notified Body (at a fee of course), along with updates to the Clinical Evidence Report. The exemptions from conformity for custommade devices are very substantially removed. All class III implantable custom made devices will be required to undergo conformity assessment irrespective of quantity produced
SPECIFICATIONS
The MDR plans to allow the EU Commission or expert panels to be defined to publish common specifications, which shall then be taken into account by manufacturers as well as Notified Bodies. These Common Specifications shall exist in parallel to the Harmonized Standards and the State of the Art.
HOW MANUFACTURER CAN PREPARE FOR ADOPTING THE NEW MDR
The complex development process for most types of medical devices, combined with the need to address new regulatory requirements and obtain Notified Body approval, is likely to make the transition a complicated and time consuming process for most device manufacturers. Further, currently approved devices are not exempt from the requirements of the new regulation and will need to be re-evaluated and re-approved. Manufacturers of currently approved medical devices will have a transition time of three years until May 26 th 2020 to meet the requirements of the MDR. Medical device manufacturers are well advised to stay current on the progress of the MDR through the legislative process, as well as additional changes that may impact them. In addition, since a large number of medical devices will now require Notified Body review and approval, delays in the review and approval process by Notified Body should be expected. Therefore, it is recommended that manufacturers of currently approved devices consult with their respective Notified Body to evaluate potential compliance issues and to develop a plan to address them promptly. Advanced preparation and early action will be key to ensuring a smooth transition to the new requirements. Control of high-risk devices such as implants involve also panels of independent experts at EU level, Clinical trials taking place in more than one Member State will be subject to a single coordinated assessment, Many aesthetic products are regulated as medical devices and subject to stricter controls, Four out of five in vitro diagnostic medical devices are checked by a Notified Body before they are placed on the market, European database contains extensive information on medical devices, most of which is publicly available. An "implant card" for implanted devices gives patients more information, A financial mechanism ensures patients are compensated in case defective medical devices harm them, Simplified procedure allows manufacturers to register their device only once at the EU level.
